Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Junctophilin-3 (JPH3) is a membrane-associated scaffold protein encoded by the JPH3 gene, primarily expressed in the brain, especially in neurons involved in motor coordination and memory[1][2][4]. It is a member of the junctophilin family, whose proteins form junctional membrane complexes linking the plasma membrane with the endoplasmic reticulum, facilitating precise calcium ion signaling essential for neuronal excitability and function[1][2][3][4][5]. The JPH3 gene contains a CAG/CTG trinucleotide repeat, and expansion of this repeat causes Huntington's disease-like 2 (HDL2), a rare neurodegenerative disorder clinically similar to Huntington’s disease[1][2][4]. In the context of cancer, JPH3 has been identified as a methylated tumor suppressor gene in colorectal and gastric cancers; loss or silencing of JPH3 promotes cancer cell proliferation and migration, while its re-expression induces apoptosis through mitochondrial pathways, partly by altering calcium homeostasis[5]. As of this writing, no approved drugs are known to target JPH3 directly, and it serves as a genetic and epigenetic biomarker for certain disorders[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Junctophilin-3 (JPH3).